- Ayrmid Ltd. has expanded its strategic partnership with RoslinCT to include a commercial supply agreement for Omisirge® (omidubicel-onlv).
- RoslinCT will complete technology transfer and support commercial manufacturing at its cGMP cell therapy facility in Hopkinton, Massachusetts.
Ayrmid Ltd., the parent company of Gamida Cell Inc, has announced an expansion of its strategic partnership with RoslinCT to include a commercial supply agreement supporting the production of Omisirge® (omidubicel-onlv). RoslinCT operates as a contract development and manufacturing organisation (CDMO) providing cell and gene therapy contract manufacturing services.
The agreement follows positive clinical trial results and FDA approval of Omisirge® for a second indication, expanding its use in the treatment of haematology patients. Under the commercial supply arrangement, RoslinCT will complete technology transfer activities and support commercial manufacturing for the additional indication.
Manufacturing will take place at RoslinCT’s cGMP cell therapy manufacturing facility in Hopkinton, Massachusetts. According to the companies, the expanded partnership is intended to support US-based manufacturing and long-term patient supply for Omisirge®.
“We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe aplastic anemia.”
Dr Joe Wiley, Chairman and Chief Executive Officer of Ayrmid Ltd
“The expansion of Omisirge®’s commercial manufacturing at RoslinCT demonstrates the strength of our partnership and the capability of our facilities to support innovative therapies at scale.”
Peter Coleman, Chief Executive Officer of RoslinCT
